Durvalumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Durvalumab
ATC codes	L01FF03
Medicine type	Biological agent
EML status history	Application rejected in 2023 (TRS 1049) for Other specified malignant neoplasms of bronchus or lung Application rejected in 2025 (TRS 1064) for Malignant neoplasm of intrahepatic bile ducts Application rejected in 2025 (TRS 1064) for Malignant neoplasms of gallbladder Application rejected in 2025 (TRS 1064) for Malignant neoplasms of biliary tract, distal bile duct Application rejected in 2025 (TRS 1064) for Hepatocellular carcinoma of liver Application rejected in 2025 (TRS 1064) for Malignant neoplasms of proximal biliary tract, cystic duct
Therapeutic equivalent for	
Wikipedia	Durvalumab
DrugBank	Durvalumab

Recommendations

Section Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of biliary tract, distal bile duct

Hepatocellular carcinoma of liver

Malignant neoplasms of proximal biliary tract, cystic duct